Psychotropics and Hepatic Issues: Nonalcoholic Fatty Liver Disease

<p>How important are ALT and AST abnormalities when prescribing psychotropics? Should you adjust dosing in patients with elevated ALT and AST? Does inflammation alter drug kinetics?</p> <p>Faculty: Jonathan Meyer, M.D.<br /> Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC095"> <strong>Learn more about Premium Membership here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/use-of-psychotropics-in-patients-with-hepatic-issues-2582?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC095"> <strong>Earn 1 CME: Use of Psychotropics in Patients With Hepatic Issues</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/diagnosis-and-impact-on-drug-metabolism-of-nonalcoholic-fatty-liver-disease-steatosis-and-nonalcoholic-steatohepatitis-2582-5007?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC095"> <strong>Diagnosis and Impact on Drug Metabolism of Nonalcoholic Fatty Liver Disease: Steatosis and Nonalcoholic Steatohepatitis</strong></a></li> </ul>